Bortezomib

Approved Uses

Bortezomib is primarily used to treat two types of cancer in adults:

• Multiple Myeloma: This is a cancer that develops in plasma cells, which are white blood cells found in the bone marrow. Bortezomib may be used as a first-line treatment or for patients whose cancer has returned or did not respond to other therapies. It is often used in combination with other chemotherapy drugs or steroids.
• Mantle Cell Lymphoma: This is a fast-growing type of non-Hodgkin lymphoma that affects the B-cells of the immune system. Bortezomib is typically used for patients with mantle cell lymphoma who have already received at least one other type of treatment.

This medication works by interfering with certain proteins in cancer cells, which helps stop the cells from growing and causes them to die.

Mechanism of Action

Bortezomib belongs to a class of medications known as proteasome inhibitors. To understand how it works, it is helpful to think of proteasomes as the recycling centers or garbage disposals of a cell. Their job is to break down and remove old or damaged proteins that the cell no longer needs.

When bortezomib enters a cell, it blocks the activity of these proteasomes. This causes a backup of proteins that would normally be cleared away. As these proteins accumulate, they disrupt the cell's internal balance and interfere with the signals the cell uses to grow and survive.

This disruption eventually leads to the following effects:

• Cell Cycle Arrest: The cell stops its normal process of dividing and multiplying.
• Apoptosis: The buildup of proteins triggers a process of programmed cell death.

While bortezomib can affect both healthy and cancerous cells, cancer cells are often more sensitive to this process. Because cancer cells grow and divide rapidly, they produce more waste proteins and rely more heavily on proteasomes to stay healthy. By blocking this system, bortezomib makes it difficult for cancer cells to survive.

Common Side Effects

Bortezomib frequently causes digestive and systemic symptoms. Common side effects include:

• Nausea, vomiting, and loss of appetite
• Diarrhea or constipation
• Feeling tired or weak
• Fever or chills
• Headache
• Blurred vision
• Rash or irritation where the medication was injected

Serious Side Effects

Some side effects can be severe and may require a change in treatment. Seek medical help immediately for:

• Nerve Damage: New or worsening numbness, tingling, burning, or pain in the hands or feet (peripheral neuropathy).
• Blood Disorders: Unusual bruising or bleeding, pale skin, extreme tiredness, or signs of infection like a persistent sore throat and fever.
• Organ Problems: Shortness of breath, swelling of the feet or ankles, yellowing of the skin or eyes, or dark-colored urine.
• Tumor Lysis Syndrome: This can cause symptoms like muscle cramping, heart palpitations, or decreased urination due to the rapid death of cancer cells.
• Brain and Vision Changes: Sudden confusion, seizures, or significant changes in vision.

Fatal Administration Warning

Bortezomib must never be administered into the spinal fluid (intrathecal administration). This route of administration is fatal and has resulted in death. The medication is only intended for intravenous or subcutaneous use.

Peripheral Neuropathy

Bortezomib frequently causes peripheral neuropathy, which is damage to the nerves, typically in the hands and feet. Symptoms may include numbness, tingling, burning sensations, or pain. This condition can be severe and may require changes to the dose, the schedule, or the way the medication is administered. Patients with pre-existing neuropathy may be at a higher risk for worsening symptoms.

Hypotension

Low blood pressure, particularly orthostatic hypotension (a drop in blood pressure when standing up), is a known risk. This can lead to dizziness, lightheadedness, or fainting. Patients with a history of fainting, those who are dehydrated, or those taking medications for high blood pressure may be at increased risk.

Cardiac and Pulmonary Toxicity

Serious heart-related issues, including the development or worsening of congestive heart failure and decreased heart function, have been reported. Additionally, some patients may experience acute lung inflammation or respiratory distress. Monitoring for symptoms such as shortness of breath, new or worsening cough, or swelling of the feet and legs is standard during treatment.

Blood Disorders

Treatment can cause a significant decrease in blood cell counts, specifically platelets (thrombocytopenia) and white blood cells (neutropenia). This increases the risk of bruising, bleeding, and infection. Blood counts are typically monitored before each dose to ensure they are at safe levels for continued treatment.

Gastrointestinal Effects

Severe nausea, vomiting, diarrhea, and constipation can occur. In some cases, these symptoms lead to severe dehydration or electrolyte imbalances that require medical intervention or hospitalization.

Other Serious Risks

• Liver Toxicity: Cases of liver failure and hepatitis have been reported. Liver function tests are usually performed regularly during therapy.
• Posterior Reversible Encephalopathy Syndrome (PRES): This rare neurological disorder can cause seizures, high blood pressure, headaches, and vision loss. It is often reversible if the medication is stopped.
• Tumor Lysis Syndrome: The rapid breakdown of cancer cells can cause chemical imbalances in the blood that may lead to kidney damage.
• Embryo-Fetal Toxicity: Bortezomib can cause harm to an unborn baby. Effective contraception is recommended for both men and women during treatment and for a period after the final dose.

Pregnancy

Bortezomib may cause harm to a fetus if used during pregnancy. Animal studies have shown that the drug can be toxic to a developing embryo. Healthcare providers typically require a pregnancy test for individuals of reproductive potential before starting treatment to ensure they are not pregnant.

Effective contraception is recommended for patients and their partners during and after treatment:

• Women: Use reliable birth control during treatment and for seven months after the final dose.
• Men: Use reliable birth control during treatment and for four months after the final dose if your partner is able to become pregnant.

If you become pregnant or suspect you are pregnant while receiving this medication, contact your healthcare provider to discuss the potential risks to the fetus.

Breastfeeding

It is currently unknown if bortezomib passes into human breast milk. Due to the risk of serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for two months following the last dose. Patients should consult with their medical team to determine the safest way to feed their infant during this time.

Available Forms

Bortezomib is supplied in the following form:

• Lyophilized Powder for Injection: This is a sterile, dry powder or cake contained in a single-dose vial.

Administration Methods

Before administration, a healthcare provider must reconstitute the powder with a specific liquid. Once prepared, the medication is given in one of two ways:

• Intravenous Injection: The medication is injected directly into a vein.
• Subcutaneous Injection: The medication is injected into the fatty tissue just beneath the skin, typically in the thigh or abdomen.

FDA Approval History

The U.S. Food and Drug Administration (FDA) first approved bortezomib in 2003 under the brand name Velcade. Initially approved for patients with multiple myeloma who had received at least two prior therapies, its use has since been expanded to include earlier stages of treatment and other conditions.

Approved Indications

Bortezomib is currently FDA-approved for the treatment of:

• Multiple Myeloma: It is used to treat adults with newly diagnosed multiple myeloma and those whose cancer has returned or did not respond to previous treatments.
• Mantle Cell Lymphoma: It is approved for the treatment of adults with mantle cell lymphoma.

The medication is approved for use as a single agent or in combination with other drugs, such as dexamethasone, melphalan, prednisone, or daratumumab, depending on the patient's treatment history and the specific type of cancer being treated.

Regulatory Status and Safety

Bortezomib is available as a generic medication. It is administered by a healthcare professional as an injection, either into a vein (intravenous) or under the skin (subcutaneous). While it is a potent chemotherapy agent, it does not currently carry a boxed warning, which is the FDA's most serious type of warning. However, it is subject to standard regulatory monitoring for safety and efficacy.

Factors Affecting Cost

The total expense for bortezomib therapy can vary significantly based on several factors:

• Generic vs. Brand Name: Bortezomib is available as the brand-name drug Velcade and as a generic medication. Generic versions typically cost less than the brand-name equivalent.
• Insurance Coverage: Most insurance plans, including Medicare and private health insurance, generally cover bortezomib. However, out-of-pocket costs such as copayments, coinsurance, or deductibles will depend on the specific plan.
• Administration Setting: Because bortezomib must be administered by a healthcare professional as an injection or infusion, the total cost often includes facility fees and professional service charges in addition to the price of the drug itself.

Financial Assistance Programs

Patients may have access to resources that help manage the costs of bortezomib:

• Manufacturer Assistance: Some pharmaceutical companies offer patient assistance programs or savings cards to help eligible individuals reduce their out-of-pocket expenses.
• Support Organizations: Certain non-profit organizations provide financial aid or grants to patients receiving treatment for conditions like multiple myeloma or mantle cell lymphoma.

Patients are encouraged to consult with their healthcare provider, hospital billing department, or insurance company to obtain a detailed estimate of costs based on their specific treatment plan and coverage.